Tech Daily Utah
SEE OTHER BRANDS

Fresh news on science and technology in Utah

Tech Daily Utah: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Tech Daily Utah.

Press releases published on May 23, 2025

As Bitcoin Hits New All-Time Highs, DN Miner Says It’s the Perfect Time to Add Cloud Mining to Your Strategy

As Bitcoin Hits New All-Time Highs, DN Miner Says It’s the Perfect Time to Add Cloud Mining to Your Strategy

London, UK, May 23, 2025 (GLOBE NEWSWIRE) -- Bitcoin has once again surged past its all-time high, reigniting excitement across the crypto market and sending investor confidence soaring. But while many are celebrating record-breaking gains, DN Miner, a …

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

Invivyd Announces Inclusion of PEMGARDA® (pemivibart) in National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for B-Cell Lymphomas

WALTHAM, Mass., May 23, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), today announced that PEMGARDA® (pemivibart), its investigational monoclonal antibody, has been added to the National Comprehensive Cancer Network® (NCCN®) Clinical Practice …

Phunware Showcases Next-Gen Guest Experience Technology at HITEC 2025

Phunware Showcases Next-Gen Guest Experience Technology at HITEC 2025

Phunware to Debut Hospitality AI Features to Streamline Mobile Interactions; Joins Industry Leaders in Discussing How Next-Gen Apps Are Redefining Guest Engagement AUSTIN, Texas, May 23, 2025 (GLOBE NEWSWIRE) -- Phunware, Inc. (NASDAQ: PHUN), a leading …

Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago

Instil Bio and ImmuneOnco to Host Investor and Analyst Breakfast to Discuss the Evolving PD-(L)1xVEGF Bispecific Antibody Landscape and Clinical Trial Updates During the 2025 ASCO Annual Meeting in Chicago

DALLAS and SHANGHAI, May 23, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, "Instil") and ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKEX Code: 1541.HK, “ImmuneOnco”), today announced that they will jointly host an investor and research …

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease

NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a …

イノベーションの価値で信頼あるパートナーシップを結集 半導体サプライチェーンのレジリエンスとグローバル展開を共に構築

イノベーションの価値で信頼あるパートナーシップを結集 半導体サプライチェーンのレジリエンスとグローバル展開を共に構築

TAIPEI, Taiwan, May 23, 2025 (GLOBE NEWSWIRE) -- 地政学的リスクの高まりと供給網の再編が進む中、ITRIは本日(5月23日)、「グローバル半導体サプライチェーン・パートナー・フォーラム」を開催。台湾政府が提唱する「グローバル半導体民主的サプライチェーン・パートナーシップ・イニシアティブ」の実践を目指し、頼清徳総統、郭智輝経済部長、ITRI劉文雄院長、日米欧など各国代表が出席、700名以上の関係者が参加した。 頼総統は、台湾のICT …

Jitterbit Placed in 2025 Gartner® Magic Quadrant™ for Integration Platform as a Service

Jitterbit Placed in 2025 Gartner® Magic Quadrant™ for Integration Platform as a Service

ALAMEDA, Calif., May 23, 2025 (GLOBE NEWSWIRE) -- Jitterbit, a global leader in accelerating business transformation for enterprise systems, today announced that it has been positioned by Gartner as a Visionary in the Magic Quadrant™ for iPaaS, core to the …

Bilibili Inc. Announces Completion of US$690 Million Convertible Senior Notes and Offering of Class Z Ordinary Shares in Connection with Hedging Transactions of Certain Convertible Notes Investors and Terms of Concurrent Repurchase

Bilibili Inc. Announces Completion of US$690 Million Convertible Senior Notes and Offering of Class Z Ordinary Shares in Connection with Hedging Transactions of Certain Convertible Notes Investors and Terms of Concurrent Repurchase

SHANGHAI, May 23, 2025 (GLOBE NEWSWIRE) -- Bilibili Inc. (“Bilibili” or the “Company”) (Nasdaq: BILI and HKEX: 9626), an iconic brand and a leading video community for young generations in China, today announced (i) the completion of its offering (the “ …

Huize Holding Limited to Report First Quarter 2025 Financial Results on June 6, 2025

Huize Holding Limited to Report First Quarter 2025 Financial Results on June 6, 2025

SHENZHEN, China, May 23, 2025 (GLOBE NEWSWIRE) -- Huize Holding Limited, (“Huize”, the “Company” or “we”) (NASDAQ: HUIZ), a leading insurance technology platform connecting consumers, insurance carriers and distribution partners digitally through data- …

VIRTUNE BESCHLEUNIGT EUROPÄISCHE EXPANSION MIT XRP-ETP-DEBÜT AN DER DEUTSCHE BÖRSE XETRA

VIRTUNE BESCHLEUNIGT EUROPÄISCHE EXPANSION MIT XRP-ETP-DEBÜT AN DER DEUTSCHE BÖRSE XETRA

Frankfurt, 23. Mai 2025 – Der schwedische regulierte Krypto-Vermögensverwalter Virtune bringt eines seiner Flaggschiffproduket, den Virtune XRP ETP, an Deutschlands führenden Handelsplatz Deutsche Börse Xetra und erweitert damit sein reguliertes Angebot …

VIRTUNE ACCELERATES EUROPEAN EXPANSION WITH XRP ETP DEBUT ON DEUTSCHE BÖRSE XETRA

VIRTUNE ACCELERATES EUROPEAN EXPANSION WITH XRP ETP DEBUT ON DEUTSCHE BÖRSE XETRA

Frankfurt, 23 May 2025 – Swedish regulated crypto asset manager Virtune brings its flagship Virtune XRP ETP to Germany's premier trading venue Deutsche Börse Xetra, extending its regulated digital asset offerings to Europe's largest economy. With strong …

Inventiva reports 2025 First Quarter Financial Information¹

Inventiva reports 2025 First Quarter Financial Information¹

Cash and cash equivalents at €67.9 million Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral …

Inventiva publie ses informations financières¹ du 1er trimestre 2025

Inventiva publie ses informations financières¹ du 1er trimestre 2025

Trésorerie et équivalents de trésorerie à 67,9 millions d’euros Daix (France), New York City (New York, Etats-Unis), le 23 mai 2025 – Inventiva (Euronext Paris et NASDAQ : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans …

Results of the Votes of the Combined Shareholders’ General Meeting of May 22, 2025

Results of the Votes of the Combined Shareholders’ General Meeting of May 22, 2025

Daix (France), New York City (New York, United States), May 23, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic …

Résultats des Votes de l’Assemblée Générale Mixte des Actionnaires Réunies le 22 mai 2025

Résultats des Votes de l’Assemblée Générale Mixte des Actionnaires Réunies le 22 mai 2025

Daix (France), New York City (New York, Etats-Unis), le 23 mai 2025 – Inventiva (Euronext Paris et NASDAQ : IVA) (« Inventiva » ou la « Société »), société biopharmaceutique spécialisée dans le développement de thérapies orales pour le traitement de la …

OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025

OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025

OSE Immunotherapeutics Announces that its Partner Boehringer Ingelheim Will Present Early Clinical Evidence of Innate Immune Modulation and Anti-Tumor Activity via SIRPα Blockade in Two Ongoing Trials at ASCO 2025 BI 765063 in combination with programmed …

OSE Immunotherapeutics annonce que son partenaire Boehringer Ingelheim présentera des premières données cliniques issues de deux essais en cours

OSE Immunotherapeutics annonce que son partenaire Boehringer Ingelheim présentera des premières données cliniques issues de deux essais en cours

OSE Immunotherapeutics annonce que son partenaire Boehringer Ingelheim présentera des premières données cliniques issues de deux essais en cours sur la modulation de l’immunité innée et l’activité antitumorale via le blocage de SIRPα à l’ASCO 2025 BI …

El servicio nacional Drones como un Servicio (DaaS) de ZenaTech crece con el cierre de su quinta adquisición, sumando capacidades de inspección de líneas eléctricas

El servicio nacional Drones como un Servicio (DaaS) de ZenaTech crece con el cierre de su quinta adquisición, sumando capacidades de inspección de líneas eléctricas

VANCOUVER, Columbia Británica, May 22, 2025 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) ("ZenaTech"), una empresa de tecnología especializada en drones con IA (Inteligencia Artificial), Dron como un Servicio (DaaS), soluciones …

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock

Gyre Therapeutics Announces Pricing of $20.0 Million Public Offering of Common Stock

SAN DIEGO, May 22, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biotechnology company focused on organ fibrosis, today announced the pricing of its previously announced underwritten public offering of …

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new data from several studies of compounds discovered by HUTCHMED including savolitinib, …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service